10 results match your criteria: "Kansas Foundation for Clinical Pharmacology[Affiliation]"
Int J Clin Pract
September 2008
Cardiometabolic Risk Factors Prevention and Treatment Programs, Kansas Foundation for Clinical Pharmacology and Therapeutics, Mission, KS 66205, USA.
Aims: This report examined the safety and efficacy of treatment for up to 2 years with the cholesterol absorption inhibitor, ezetimibe (EZE).
Methods: Two identical, randomised, double-blind trials (starting with 827 and 892 patients), evaluated the efficacy and safety of EZE 10 mg/day vs. placebo for 12 weeks in patients with primary hypercholesterolaemia [low-density lipoprotein cholesterol (LDL-C) 3.
Curr Treat Options Cardiovasc Med
August 2004
Kansas Foundation for Clinical Pharmacology and Therapeutics, 12200 W. 106th Street, Suite 330, Overland Park, KS 66215, USA. E mail:
Despite their inherited nature, familial dyslipidemias show large intra- and interfamilial variability in phenotypic expression, clinical presentations, and levels of abnormalities of serum lipid fractions. Once diagnosed, patients shall be considered at high cardiovascular risk and treated as per secondary prevention National Cholesterol Education Program III guidelines. Comorbidity treatments (ie, obesity, diabetes, and hypertension) are imperative.
View Article and Find Full Text PDFExpert Opin Pharmacother
May 2003
Kansas Foundation for Clinical Pharmacology, Radiant Research, Kansas City, 12200 W 106th, Overland Park, KS 66215, USA.
Colesevelam HCl (WelChol, Sankyo Pharmaceuticals Inc.) is a bile acid sequestrant polymer, which has been shown to significantly lower low density lipoprotein cholesterol and favourably affect high-density lipoprotein cholesterol blood levels in monotherapy and in combination with statins (HMG-CoA reductase inhibitors). Although it is similar to other bile acid sequestrants in that it binds bile acids and is non-systemic, colesevelam HCl differs in that it has a unique polymer structure that allows for greater tolerability with less potential drug interactions than with resins.
View Article and Find Full Text PDFAm J Cardiol
November 2002
Kansas Foundation for Clinical Pharmacology, Radiant Research-Kansas City, 12200 W. 106th Street, Suite 330, Overland Park, KS 66215, USA.
The efficacy and safety of ezetimibe, a new cholesterol absorption inhibitor, was evaluated in this randomized, double-blind, placebo-controlled trial of 892 patients with primary hypercholesterolemia. After > or =2 weeks on the National Cholesterol Education Program (NCEP) Step I or a stricter diet and a 4- to 8-week single-blind placebo lead-in, patients with low-density lipoprotein (LDL) cholesterol 130 to 250 mg/dl and triglycerides < or =350 mg/dl were randomized 3:1 to receive ezetimibe 10 mg or placebo orally each morning for 12 weeks. The primary efficacy end point was the percent reduction in direct plasma LDL cholesterol from baseline to end point.
View Article and Find Full Text PDFAm Heart J
September 2001
Kansas Foundation for Clinical Pharmacology, Radiant Research-Kansas City, Overland Park, Kan, USA.
Background: Cardiovascular risk factors associated with obesity, including dyslipidemia, can be improved by weight loss. The main dyslipidemia associated with obesity is elevated serum triglyceride and decreased serum high-density lipoprotein cholesterol (HDL-C) levels.
Methods: A total of 322 obese patients (body mass index > or = 27) with serum triglyceride levels > or = 250 mg/dL and < or = 1000 mg/dL and serum HDL-C levels < or = 45 mg/dL (women) and < or = 40 mg/dL (men) were placed on a step I American Heart Association diet and subsequently randomized to sibutramine 20 mg (n = 162) or placebo (n = 160) once daily for 24 weeks.
Expert Opin Investig Drugs
March 2001
Radiant Research, Kansas Foundation for Clinical Pharmacology, 12200 W. 106th St., Ste. 330, Overland Park, KS 66215, USA.
Coronary heart disease (CHD), whose primary aetiology is atherosclerosis, is the leading cause of mortality and a major cause of morbidity in the industrialised world [1]. Serum lipoprotein levels are aetiologically related to the risk of atherosclerosis and CHD [2]. The liver and the gastrointestinal system are the major protagonists involved in regulation of lipoprotein biochemical-physiological mechanisms and the development of hypercholesterolaemia.
View Article and Find Full Text PDFJ Clin Pharmacol
January 2001
Kansas Foundation for Clinical Pharmacology, Radiant Research Center-Kansas City, 12200 W. 106th, Suite 330, Overland Park, KS 66215, USA.
SCH 48461, an inhibitor of gastrointestinal absorption of cholesterol, was evaluated for its effects on lipid parameters in patients with primary hypercholesterolemia in a multicenter, double-blind, randomized, parallel-group study. Following the baseline phase, which consisted of a 2- to 10-week drug washout and dietary stabilization phase and a 4-week placebo lead-in (placebo baseline phase), 190 patients were randomized to an 8-week double-blind active drug (SCH 48461 1, 6.25, 25, 100, 200, or 400 mg) or 40 mg lovastatin once daily each morning or placebo treatment phase.
View Article and Find Full Text PDFCurr Atheroscler Rep
January 2000
Kansas Foundation for Clinical Pharmacology, Radiant Research, Kansas City, 10550 Quivira Road, Suite 220, Overland Park, KS 66215, USA.
The purpose of this review article is twofold. It seeks to present an overview of research studies conducted on the many effects of probucol, and it demonstrates the interest in pursuing studies on probucol"s multiple specific actions and its future as a therapeutic agent. Within this article, the results of animal studies, experimental human studies, and clinical human studies are detailed, as is information on toxicology studies and on the side effects of the drug.
View Article and Find Full Text PDFMayo Clin Proc
November 2000
Kansas Foundation for Clinical Pharmacology, Radiant Research, Kansas City, Overland Park 66215, USA.
Objective: To determine the relative efficacy and safety of cerivastatin and pravastatin in patients with type II hypercholesterolemia.
Patients And Methods: In this prospective, double-blind, parallel-group study, hypercholesterolemic patients were randomized to treatment with cerivastatin, 0.3 mg (n=250) or 0.
Am J Med
August 1999
Kansas Foundation for Clinical Pharmacology, Radiant Research, Kansas City 66215, USA.